– Announces successful completion of the Phase 1B portion of its Phase 1B/2 clinical trial Annamycin in combination with Cytarabine for the treatment of AML.
Moleculin Biotech (MBRX) Provides Update on Ongoing Clinical Trials and Outlines Expected Upcoming Milestones streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
HOUSTON, Aug. 7, 2023 /PRNewswire/ Moleculin Biotech, Inc., , a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today.
/PRNewswire/ Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug.
Moleculin Biotech (MBRX) Announces Publication of Data from Successful European Phase 1 Trial of Annamycin streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.